Evidence map›Paper›PMID 26658902›Full record

Trial reportPloS one2015

Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.

Alienke J Wijmenga-Monsuur, Els van Westen, Mirjam J Knol, Riet M C Jongerius, Marta Zancolli, David Goldblatt, Pieter G M van Gageldonk, Irina Tcherniaeva, Guy A M Berbers, Nynke Y Rots

Erratum issuedOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Alienke J Wijmenga-MonsuurCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
Els van WestenCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
Mirjam J KnolCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
Riet M C JongeriusCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
Marta ZancolliUniversity College London, Institute of Child Health, London, United Kingdom.
David GoldblattUniversity College London, Institute of Child Health, London, United Kingdom.
Pieter G M van GageldonkCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
Irina TcherniaevaCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
Guy A M BerbersCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
Nynke Y RotsCentre for Infectious Disease Control, National institute for Public Health and the Environment, Bilthoven, The Netherlands.
National Institute for Public Health and the Environment · NLUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsSince 2009/10, a 10- and a 13-valent pneumococcal conjugate vaccine (PCV) are available, but only the 10-valent vaccine is now being used for the children in the Netherlands. As the vaccines differ in number of serotypes, antigen concentration, and carrier proteins this study was designed to directly compare quantity and quality of the antibody responses induced by PCV10 and PCV13 before and after the 11-month booster.

methodsDutch infants (n = 132) were immunized with either PCV10 or PCV13 and DTaP-IPV-Hib-HepB at the age of 2, 3, 4 and 11 months. Blood samples were collected pre-booster and post-booster at one week and one month post-booster for quantitative and qualitative immunogenicity against 13 pneumococcal serotypes, as well as quantitative immunogenicity against diphtheria, tetanus, pertussis and Haemophilus influenzae type b. We compared immunogenicity induced by PCV13 and PCV10 for their ten shared serotypes.

resultsOne month post-booster, pneumococcal serotype-specific IgG geometric mean concentrations (GMCs) for the PCV13 group were higher compared with the PCV10 group for six serotypes, although avidity was lower. Serotype 19F showed the most distinct difference in IgG and, in contrast to other serotypes, its avidity was higher in the PCV13 group. One week post-booster, opsonophagocytosis for serotype 19F did not differ significantly between the PCV10- and the PCV13 group.

conclusionBoth PCV10 and PCV13 were immunogenic and induced a booster response. Compared to the PCV10 group, the PCV13 group showed higher levels for serotype 19F GMCs and avidity, pre- as well as post-booster, although opsonophagocytosis did not differ significantly between groups. In our study, avidity is not correlated to opsonophagocytotic activity (OPA) and correlations between IgG and OPA differ per serotype. Therefore, besides assays to determine IgG GMCs, assays to detect opsonophagocytotic activity, i.e., the actual killing of the pneumococcus, are important for PCV evaluation. How differences between the two vaccines relate to long-term protection requires further investigation.

trial registrationwww.trialregister.nl NTR3069.

Indexed as

Antibodies, BacterialAntibody FormationChild, PreschoolDiphtheriaDiphtheria-Tetanus-Pertussis VaccineHaemophilus InfectionsHaemophilus influenzae type bHaemophilus VaccinesHepatitis B VaccinesHumansImmunization ScheduleImmunization, SecondaryImmunoglobulin GInfantNetherlandsPneumococcal Infections10-valent pneumococcal conjugate vaccine13-valent pneumococcal vaccineAntibodies, Bacterialdiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B VaccinesImmunoglobulin GPneumococcal VaccinesPoliovirus Vaccine, InactivatedVaccines, CombinedVaccines, Conjugate

Identifiers

PMID26658902
PMCPMC4690595
OpenAlexW2195509691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.